{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:42:20Z","timestamp":1791531740389,"version":"4.3.4"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CTQ2015-68756-R"],"award-info":[{"award-number":["CTQ2015-68756-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fumarylacetoacetate hydrolase (FAH) is the fifth enzyme in the tyrosine catabolism pathway. A deficiency in human FAH leads to hereditary tyrosinemia type I (HT1), an autosomal recessive disorder that results in the accumulation of toxic metabolites such as succinylacetone, maleylacetoacetate, and fumarylacetoacetate in the liver and kidney, among other tissues. The disease is severe and, when untreated, it can lead to death. A low tyrosine diet combined with the herbicidal nitisinone constitutes the only available therapy, but this treatment is not devoid of secondary effects and long-term complications. In this study, we targeted FAH for the first-time to discover new chemical modulators that act as pharmacological chaperones, directly associating with this enzyme. After screening several thousand compounds and subsequent chemical redesign, we found a set of reversible inhibitors that associate with FAH close to the active site and stabilize the (active) dimeric species, as demonstrated by NMR spectroscopy. Importantly, the inhibitors are also able to partially restore the normal phenotype in a newly developed cellular model of HT1.<\/jats:p>","DOI":"10.3390\/ijms22041789","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:12:10Z","timestamp":1613146330000},"page":"1789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-6478","authenticated-orcid":false,"given":"Jon","family":"Gil-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iratxe","family":"Macias","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-8783","authenticated-orcid":false,"given":"Luca","family":"Unione","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"},{"name":"ATLAS Molecular Pharma, Bizkaia Technology Park, Bld. 800, 48160 Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-3844","authenticated-orcid":false,"given":"Ganeko","family":"Bernardo-Seisdedos","sequence":"additional","affiliation":[{"name":"ATLAS Molecular Pharma, Bizkaia Technology Park, Bld. 800, 48160 Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-6939","authenticated-orcid":false,"given":"Fernando","family":"Lopitz-Otsoa","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fernandez-Ramos","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-9126","authenticated-orcid":false,"given":"Ana","family":"Lain","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Sanz-Parra","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Mato","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-4105","authenticated-orcid":false,"given":"Oscar","family":"Millet","sequence":"additional","affiliation":[{"name":"Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Bizkaia Technology Park, Bld. 800, Derio, 48160 Bizkaia, Spain"},{"name":"ATLAS Molecular Pharma, Bizkaia Technology Park, Bld. 800, 48160 Derio, 48160 Bizkaia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","article-title":"Tyrosinemia: A Review","volume":"4","author":"Russo","year":"2001","journal-title":"Pediatr. Dev. Pathol."},{"key":"ref_2","first-page":"43","article-title":"Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1","volume":"9","author":"Angileri","year":"2015","journal-title":"In JIMD Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tanguay, R.M., Angileri, F., and Vogel, A. (2017). Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1. Advances in Experimental Medicine and Biology, Springer Nature.","DOI":"10.1007\/978-3-319-55780-9_4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/TACG.S113310","article-title":"Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)","volume":"10","author":"Das","year":"2017","journal-title":"Appl. Clin. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-017-0696-z","article-title":"Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: A systematic review","volume":"12","author":"Geppert","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jmd2.12023","article-title":"Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion","volume":"46","author":"Jack","year":"2019","journal-title":"JIMD Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1042\/BJ20060961","article-title":"Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: Kinetics, crystal structure and pharmacokinetics","volume":"402","author":"Bateman","year":"2007","journal-title":"Biochem. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15284","DOI":"10.1074\/jbc.M007621200","article-title":"Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound Phosphorus-based Inhibitor","volume":"276","author":"Bateman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1042\/BJ20120913","article-title":"Crystal structures of Cg1458 reveal a catalytic lid domain and a common catalytic mechanism for the FAH family","volume":"449","author":"Ran","year":"2013","journal-title":"Biochem. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers6020998","article-title":"Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I","volume":"6","author":"Angileri","year":"2014","journal-title":"Cancers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13051","DOI":"10.1074\/jbc.RA119.009367","article-title":"Hereditary tyrosinemia type I\u2013associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate","volume":"294","author":"Macias","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1203\/00006450-200212000-00004","article-title":"Chemical Chaperones: A Pharmacological Strategy for Disorders of Protein Folding and Trafficking","volume":"52","author":"Perlmutter","year":"2002","journal-title":"Pediatr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000361","article-title":"Chemical and pharmacological chaperones as new therapeutic agents","volume":"9","author":"Loo","year":"2007","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eaat7467","DOI":"10.1126\/scitranslmed.aat7467","article-title":"Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria","volume":"10","author":"Urquiza","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0969-2126(99)80170-1","article-title":"Crystal structure and mechanism of a carbon\u2013carbon bond hydrolase","volume":"7","author":"Timm","year":"1999","journal-title":"Structure"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI34355","article-title":"Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria","volume":"118","author":"Pey","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1093\/hmg\/ddu298","article-title":"Tuning intracellular homeostasis of human uroporphyrinogen III synthase by enzyme engineering at a single hotspot of congenital erythropoietic porphyria","volume":"23","author":"Pluta","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13127","DOI":"10.1074\/jbc.M110.205849","article-title":"Intracellular Rescue of the Uroporphyrinogen III Synthase Activity in Enzymes Carrying the Hotspot Mutation C73R","volume":"286","author":"Fortian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1021\/jm201090k","article-title":"Binding of Ibuprofen, Ketorolac, and Diclofenac to COX-1 and COX-2 Studied by Saturation Transfer Difference NMR","volume":"54","author":"Viegas","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jmr.2016.06.011","article-title":"Improving accuracy in DOSY and diffusion measurements using triaxial field gradients","volume":"270","author":"Kiraly","year":"2016","journal-title":"J. Magn. Reson."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/mrc.1256","article-title":"Methyl TROSY: Explanation and experimental verification","volume":"41","author":"Ollerenshaw","year":"2003","journal-title":"Magn. Reson. Chem."},{"key":"ref_22","first-page":"2132","article-title":"Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient","volume":"125","author":"Cao","year":"2012","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ped.12503","article-title":"Hereditary tyrosinemia type 1 in Turkey: Twenty year single-center experience","volume":"57","author":"Kiykim","year":"2015","journal-title":"Pediatr. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1442-200X.2011.03427.x","article-title":"Tyrosinemia type 1 in Spain: Mutational analysis, treatment and long-term outcome","volume":"53","author":"Couce","year":"2011","journal-title":"Pediatr. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/0471250953.bi0814s24","article-title":"Using AutoDock for ligand-receptor docking","volume":"24","author":"Morris","year":"2008","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1093\/emboj\/20.21.5832","article-title":"Crystal structure of human uroporphyrinogen III synthase","volume":"20","author":"Mathews","year":"2001","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1073\/pnas.1800235115","article-title":"Structural basis and energy landscape for the Ca 2+ gating and calmodulation of the Kv7.2 K + channel","volume":"115","author":"Malo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2014Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/abio.1996.9957","article-title":"Spectrophotometric Determination of Homogentisate UsingAspergillus nidulansHomogentisate Dioxygenase","volume":"245","year":"1997","journal-title":"Anal. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/jmre.1998.1491","article-title":"Efficient Simulation of Coherence Transfer Pathway Selection by Phase Cycling and Pulsed Field Gradients in NMR","volume":"134","author":"Jerschow","year":"1998","journal-title":"J. Magn. Reson."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/cc980004o","article-title":"Affinity NMR: Decoding DNA Binding","volume":"1","author":"Anderson","year":"1999","journal-title":"J. Comb. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-5793(02)02508-5","article-title":"NMR measurement of the off rate from the first calcium-binding site of the synaptotagmin I C 2 A domain","volume":"516","author":"Millet","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nevozhay, D. (2014). Cheburator software for automatically calculating drug inhibitory concentrations from in vitroscreening assays. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106186"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:50Z","timestamp":1760160170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041789"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041789","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}